Dashboard
Manage Tickers

VIRVir Biotechnology, Inc.

Nasdaq vir.bio


$ 8.88 $ -0.23 (-2.53 %)    

Thursday, 27-Jun-2024 15:59:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 8.87
$ 8.94
$ 0.00 x 0
$ 0.00 x 0
$ 8.84 - $ 9.07
$ 7.61 - $ 25.37
799,977
na
1.2B
$ -0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-04-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-26-2020 12-31-2019 10-K
19 11-19-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

vir-biotechnologys-hepatitis-delta-drug-combo-receives-fda-clearance-and-fast-track-status
Vir Biotechnology's Hepatitis Delta Drug C...
06/26/2024 12:06:40

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investiga...

morgan-stanley-maintains-equal-weight-on-vir-biotechnology-raises-price-target-to-15
Morgan Stanley Maintains Equal-Weight on V...
06/06/2024 13:12:28

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Equal-Weight and raises the price tar...

why-is-infectious-disease-focused-vir-biotechnology-stock-trading-higher-on-wednesday
Why Is Infectious Disease-Focused Vir Biot...
06/05/2024 18:51:30

Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT nor...

why-lands-end-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Lands' End Shares Are Trading Lower? H...
06/05/2024 17:04:26

hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-110-price-target
HC Wainwright & Co. Reiterates Buy on Vir ...
06/05/2024 16:20:42

HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...

needham-maintains-buy-on-vir-biotechnology-raises-price-target-to-19
Needham Maintains Buy on Vir Biotechnology...
06/05/2024 16:19:01

Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to ...

ollies-bargain-outlet-posts-upbeat-earnings-joins-verint-systems-guidewire-software-and-other-big-stocks-moving-higher-on-wednesday
Ollie's Bargain Outlet Posts Upbeat Earnin...
06/05/2024 14:23:46

vir-biotechnology-announced-new-preliminary-data-from-phase-2-solstice-hepatitis-delta-trial-showing-tobevibart-alone-or-combined-with-elebsiran-was-generally-well-tolerated-and-patients-achieved-high-virologic-response-and-alt-normalization
Vir Biotechnology Announced New Preliminar...
06/05/2024 09:36:18

evaluating-vir-biotechnology-insights-from-5-financial-analysts
Evaluating Vir Biotechnology: Insights Fro...
05/24/2024 17:01:04

hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-110-price-target
HC Wainwright & Co. Reiterates Buy on Vir ...
05/24/2024 16:48:41

HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...

vir-biotechnologys-solstice-data-to-be-featured-at-the-european-association-for-the-study-of-the-liver-congress-2024
Vir Biotechnology's SOLSTICE Data To Be Fe...
05/21/2024 12:30:20

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis...

deep-dive-into-vir-biotechnology-stock-analyst-perspectives-6-ratings
Deep Dive Into Vir Biotechnology Stock: An...
05/07/2024 13:00:33

hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-110-price-target
HC Wainwright & Co. Reiterates Buy on Vir ...
05/07/2024 11:01:54

HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...

jp-morgan-maintains-neutral-on-vir-biotechnology-raises-price-target-to-12
JP Morgan Maintains Neutral on Vir Biotech...
05/03/2024 19:17:37

JP Morgan analyst Eric Joseph maintains Vir Biotechnology (NASDAQ:VIR) with a Neutral and raises the price target from $10 t...

needham-reiterates-buy-on-vir-biotechnology-maintains-15-price-target
Needham Reiterates Buy on Vir Biotechnolog...
05/03/2024 19:15:23

Needham analyst Joseph Stringer reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $15 price target.

vir-biotechnology-reiterates-fy24-gaap-combined-rd-and-sga-expense-range-650m-680m
Vir Biotechnology Reiterates FY24 GAAP Com...
05/02/2024 20:22:03

vir-biotechnology-q1-2024-gaap-eps-048-beats-107-estimate-sales-56400m-beat-11712m-estimate
Vir Biotechnology Q1 2024 GAAP EPS $(0.48)...
05/02/2024 20:10:14

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(1....

on-april-15-2024-sung-lee-executive-vice-president-and-chief-financial-officer-of-vir-biotechnology-informed-the-company-that-he-will-be-stepping-down-from-his-role-effective-may-3-2024-to-pursue-another-career-opportunity-co-has-initiated-a-search-for-his-successor
On April 15, 2024, Sung Lee, Executive Vic...
04/18/2024 12:49:08

On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the "Company&...

assessing-vir-biotechnology-insights-from-5-financial-analysts
Assessing Vir Biotechnology: Insights From...
03/15/2024 14:00:25

hc-wainwright--co-reiterates-buy-on-vir-biotechnology-maintains-110-price-target
HC Wainwright & Co. Reiterates Buy on Vir ...
03/15/2024 13:26:48

HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)